Avalyn Pharma Inc. Common Stock (AVLN) Stock

About Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

Avalyn Pharma Inc. Common Stock is led by CEO Lyn Baranowski, employs 50 people, headquartered in US, publicly traded since 2026.

Avalyn Pharma Inc. Common Stock (AVLN) stock trades at $33.75 with a market capitalization of $1.50B. The stock is valued at a price-to-earnings (P/E) ratio of -16.54, price-to-book of -5.91, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $24.15 and $33.89, and currently trades at its 52-week high.

On profitability, Avalyn Pharma Inc. Common Stock generates a return on equity (ROE) of 35.70% — well above the market average, a sign of a high-quality business, return on capital employed of -67.73%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.avalynpharma.com